 |
|
Home | Cubist Pharmaceuticals Given “Neutral” Rating at Zacks (CBST) |
 |
Cubist Pharmaceuticals Given “Neutral” Rating at Zacks (CBST)
|
 |
- March 11, 2014
-
Cubist Pharmaceuticals (NASDAQ:CBST)‘s stock had its “neutral” rating restated by Zacks in a report released on Tuesday, ARN reports. They currently have a $81.00 price objective on the stock. Zacks‘s price target indicates a potential upside of 5.56% from the company’s current price. Zacks’ analyst wrote, “Cubist’s fourth quarter 2013 adjusted earnings of $0.29 per […]This article (Cubist Pharmaceuticals Given “Neutral” Rating at Zacks (CBST)) was originally developed by and is property of American Banking News.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
- Read more at:http://www.americanbankingnews.com/2014/03/11/cubist-pharmaceuticals-given-neutral-rating-at-zacks-cbst/
|
 |
|
 |
|
 |
